

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for November 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sandoz Canada Inc.	Sandoz Ambrisentan Tablets	Volibris	AMBRISENTAN	5 mg	tablet	02526875
Sandoz Canada Inc.	Sandoz Ambrisentan Tablets	Volibris	AMBRISENTAN	10 mg	tablet	02526883
Mantra Pharma Inc	M-Ticagrelor	Brilinta	TICAGRELOR	60 mg	tablet	02529750
Nora Pharma	NRA-Tadalafil	Cialis	TADALAFIL	5 mg	tablet	02520931
Nora Pharma	NRA-Tadalafil	Cialis	TADALAFIL	20 mg	tablet	02520966
Apotex Inc.	Apo-Ticagrelor	Brilinta	TICAGRELOR	60 mg	tablet	02482622
Pharmascience Inc.	Pms-Pirfenidone	Esbriet	PIRFENIDONE	267 mg	tablet	02531526

Pharmascience Inc.	Pms-Pirfenidone	Esbriet	PIRFENIDONE	801 mg	tablet	02531534
--------------------	-----------------	---------	-------------	--------	--------	----------